CHF Solutions Announces COVID-19 Patients Treated with Aquadex Therapy for Fluid Management When Access to Dialysis Machines is Limited or Not Available
CHF Solutions, Inc.
EDEN PRAIRIE, Minn., April 14, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, announced that physicians on the frontlines of treating patients with COVID-19 have used Aquadex therapy for patients who need fluid removal between dialysis treatments as an alternative therapy when dialysis machines or trained dialysis personnel are not available. In addition, patients hemodynamically unstable and fluid overloaded, who may not be able to tolerate dialysis but still need fluid removal, are being treated with the Aquadex therapy.
The real-world case studies and related discussion were presented during a physician-led webinar hosted by CHF Solutions on April 10. Dr. Daniel J. Goldstein, MD, FACS, FACC (Montefiore Medical Center, NY, NY) moderated the panel discussion which included Dr. Maria DeVita, M.D., FACP, FASN (Lenox Hill Hospital, NY, NY), Dr. Mehdi Oloomi, M.D. (Mount Sinai Medical Center, NY, NY) and Dr. Giovanni Piovesana (Phoebe-Putney Hospital, Albany, GA).
The physicians’ discussion and recommendations were supported by a recent article published by the Clinical Journal of the American Society of Nephrology.1 In the publication, the authors concluded, “the use of other machines to replace a standard dialysis machine may have merit such as machines that only do isolated ultrafiltration to perform all isolated ultrafiltration procedures, thereby keeping standard full-size dialysis machines available to perform treatments.”
“Acute kidney injury is a significant risk for critically ill patients with COVID-19,” said Dr. DeVita. “Adequate access to dialysis equipment is a growing concern as is the growing number of patients who need fluid removal but are poor candidates for traditional dialysis. We see ultrafiltration as a valuable treatment in both instances and are seeing a clear benefit to including Aquadex therapy as a vital part of our armamentarium to treat COVID-19.”
“As we continue to learn about this novel virus, it is important that we listen to the dedicated medical professionals treating patients on the front line. We are pleased that Aquadex therapy can help critical care patients during this pandemic,” said John Erb, CEO of CHF Solutions. “As previously announced, we have increased production to meet anticipated demand and ensure that physicians, nurses and the clinical staff have the solutions they need to treat patients impacted with COVID-19. I also want to take this opportunity to thank our customers for their continued partnership with us as they find ways to treat those affected by the coronavirus and extend our most sincere gratitude to the first responders and medical teams taking care of the critically ill patients.”
1.CJASN ePress. Dwyer, et al. published on April 3, 2020 as doi: 10.2215/CJN.03750320
About CHF Solutions
CHF Solutions, Inc. (Nasdaq: CHFS) is a medical device company dedicated to improving the lives of patients suffering from fluid overload with its novel ultrafiltration therapy system. The company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow™ system for ultrafiltration therapy. CHF Solutions is headquartered in Minneapolis, Minn., with wholly-owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, un
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements about the clinical use of the Aquadex SmartFlow system in patients infected with the coronavirus COVID-19. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACTS INVESTORS: Claudia Napal Drayton Chief Financial Officer, CHF Solutions, Inc. 952-345-4205 MEDIA: Jessica Stebing Health+Commerce 260-336-6202